Health ProductsPublic Communication

Archived - Market withdrawal of Raptiva (efalizumab) in Canada- For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Biologic/vaccine
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from EMD Serono Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Public Communication
Health Canada Endorsed Important Safety Information on Raptiva (efalizumab)

June 11, 2009

Subject: Communication on the decision to withdraw Raptiva® in Canada

This Communication is to inform you about the decision for EMD Serono Canada Inc. to withdraw the market authorization of RAPTIVA in Canada.

EMD Serono Canada Inc., the company that markets RAPTIVA in Canada has in consultation with Health Canada decided to terminate the marketing of Raptiva (efalizumab) in Canada, due to safety concerns.

RAPTIVA was authorized in October 2005 for the treatment of plaque psoriasis in adult patients.

Summary:

  • Effective June 8, 2009, Raptiva will no longer be available on the Canadian market, and all markets globally.
  • The marketing of Raptiva in Canada was suspended on February 20, 2009 following the determination that the benefit of Raptiva in psoriasis patients was outweighed by the risk of developing a serious and potentially fatal brain infection. A public communication (PC) was issued in regard to the suspension of marketing of this product, at that time.
  • Health care providers in Canada were notified to switch their patients to other available alternative therapies, as Raptiva would no longer be available after 3 months.
  • All patients have now had more then 3 months to review their treatment with their health care providers and to switch to alternative psoriasis treatments.
  • Patients previously taking Raptiva, who develop any serious and/or unexpected adverse reactions should report these to a health care provider and mention that they had been previously treated with Raptiva.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any occurrence of serious and/or unexpected adverse reactions in patients who received RAPTIVA should be reported to EMD Serono Canada Inc., or Health Canada at the following addresses:

EMD Serono Canada Inc.
2695 North Sheridan Way, Suite 200
Mississauga ON L5K 2N6
Telephone: 1-888-737-6668 x 5160
Fax: 905-919-0292
E-mail: drugsafetycanada@merckserono.net

Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca

The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada Web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

Should you have any questions regarding the withdrawal of RAPTIVA, please call EMD Serono Canada Inc.’s Patient Services at 1-866-440-4245.

original signed by

Peter Grosser, Ph.D.
Director, Regulatory Affairs, Drug Safety & Medical Information
EMD Serono Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime